BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. With the acquisition,
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...
Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...
The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...
On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...
BEIJING (dpa-AFX) - BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company focused on novel antibodies, for $800 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback